154 related articles for article (PubMed ID: 22100582)
1. Targeting advanced prostate cancer.
Fillon M
J Natl Cancer Inst; 2011 Dec; 103(23):1733. PubMed ID: 22100582
[No Abstract] [Full Text] [Related]
2. Angiogenesis as a strategic target for prostate cancer therapy.
Li Y; Cozzi PJ
Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
[TBL] [Abstract][Full Text] [Related]
3. [New perspectives in the drug therapy of hormone-resistant prostate cancer].
Vorob'ev NA; Nosov AK; Vorob'ev AV; Moiseenko VM
Vopr Onkol; 2010; 56(6):645-53. PubMed ID: 21395118
[No Abstract] [Full Text] [Related]
4. Continued targeting of androgen receptor signalling: a rational and efficacious therapeutic strategy in metastatic castration-resistant prostate cancer.
Bianchini D; de Bono JS
Eur J Cancer; 2011 Sep; 47 Suppl 3():S189-94. PubMed ID: 21943974
[No Abstract] [Full Text] [Related]
5. Novel concepts in androgen receptor blockade.
Hsieh AC; Ryan CJ
Cancer J; 2008; 14(1):11-4. PubMed ID: 18303477
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone and MVD3100 take androgen deprivation to a new level.
Schmidt C
J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
[No Abstract] [Full Text] [Related]
7. New agents in metastatic prostate cancer.
Fizazi K; Massard C
Eur J Cancer; 2009 Sep; 45 Suppl 1():379-80. PubMed ID: 19775638
[No Abstract] [Full Text] [Related]
8. Prostate cancer: score one for validated targets.
Bates SE
Clin Cancer Res; 2011 Jun; 17(12):3866. PubMed ID: 21680541
[No Abstract] [Full Text] [Related]
9. New drugs in prostate cancer.
Armstrong AJ; Carducci MA
Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of advanced cancer of the prostate.
Wirth MP
Prog Clin Biol Res; 1990; 350():159-70. PubMed ID: 2201042
[No Abstract] [Full Text] [Related]
11. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Keizman D; Maimon N; Gottfried M
Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
[TBL] [Abstract][Full Text] [Related]
12. Castration-refractory prostate cancer: New drugs in the pipeline.
Schrijvers D; Van Erps P; Cortvriend J
Adv Ther; 2010 May; 27(5):285-96. PubMed ID: 20532721
[TBL] [Abstract][Full Text] [Related]
13. Novel molecular targets for prostate cancer therapy.
Kamradt JM; Pienta KJ
Semin Oncol; 1999 Apr; 26(2):234-43. PubMed ID: 10597734
[TBL] [Abstract][Full Text] [Related]
14. [Drug treatment of prostatic carcinoma].
Kool JC
Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808
[No Abstract] [Full Text] [Related]
15. Targeted therapy in prostate cancer.
Corcoran NM; Gleave ME
Histopathology; 2012 Jan; 60(1):216-31. PubMed ID: 22212088
[TBL] [Abstract][Full Text] [Related]
16. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
Sivko AV; Prokhorov AV
Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
[No Abstract] [Full Text] [Related]
17. [Complete androgen blockage in the treatment of metastatic prostate cancer].
Matzkin H; Braf Z
Harefuah; 1994 Mar; 126(5):260-3. PubMed ID: 8188104
[No Abstract] [Full Text] [Related]
18. PSA response to thalidomide in patients with advanced prostate cancer.
Leibowitz R; Tucker SJ
Oncology (Williston Park); 2002 Sep; 16(9):1146, 1148. PubMed ID: 12380944
[No Abstract] [Full Text] [Related]
19. Castration-resistant prostate cancer: targeted therapies.
Leo S; Accettura C; Lorusso V
Chemotherapy; 2011; 57(2):115-27. PubMed ID: 21430379
[TBL] [Abstract][Full Text] [Related]
20. New drugs in the management of advanced prostate cancer.
Kelly WK
Cancer J; 2008; 14(1):10. PubMed ID: 18303476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
